Project Grant R01HL175076
Award Date
7/25/25
Completion Date
4/30/29
Dollars Obligated
$805K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This Project Grant award of $602,358, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to assess the contribution of epigenetics to cardiovascular risk in African American women. The project will identify epigenetic biomarkers of cardiovascular disease and its environmental determinants, and evaluate if these biomarkers can contribute to risk prediction assessments. The research will be conducted by the...
This Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $147,486 to Baylor College of Medicine to conduct research aimed at improving genetic testing for cardiovascular disease (CVD). The key objectives are to: Study the genetics of CVD and lipoprotein(a) (Lp(a)) across diverse and mixed-ancestry populations using novel tools that appropriately evaluate ancestry. This includes evaluating the role of linkage...
This Project Grant award in the amount of $121,500.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), to The University of Texas MD Anderson Cancer Center. The goal of this research project is to investigate the molecular mechanisms by which environmental and lifestyle risk factors influence cardiovascular traits and the risk of cardiovascular disease. The researchers will leverage large-scale multi-omics...
This federal Project Grant award of $246,776.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop novel methods for creating and validating polygenic scores (PS) that can predict medication response in African American populations. The goal is to create ancestry-robust PS tools that account for local genetic ancestry context, improving their predictive performance for non-European populations. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA program 93.837 Cardiovascular Diseases Research is providing $807,948 to support a study on the genetics of left ventricular hypertrophy (LVH) and associated cardiac phenotypes. The primary awardee, The Medical College of Wisconsin, Inc. (MCW), will utilize whole genome sequencing data from the NHLBI TOPMed program to conduct association analyses and identify genetic variants related to LVH....
This federal Project Grant award of $616,786, awarded on June 1, 2025 by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports research aimed at uncovering the evolutionary mechanisms shaping genetic variation and phenotypic diversity across human populations. The key focus areas of the research include: 1) exploring the effects of recessive deleterious alleles and associative overdominance on patterns of...
This $2,559,308 Project Grant was awarded on January 14, 2025 by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports a study examining the impact of severe pre-eclampsia on heart function in a racially diverse cohort of women during and after pregnancy. The study aims to characterize the cardiomyopathic genetic profile of participants and assess the functional impact of specific genetic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $126,660 to the University of California, San Diego (UCSD) to investigate the genetic and cellular mechanisms underlying Tibetan adaptation to high altitude and the potential therapeutic use of carbon monoxide releasing molecules (CORMs) for treating pulmonary arterial hypertension. The key focus is to determine the link between Tibetan...
This $767,579 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to leverage large-scale biobanks to discover and define rare variant effects in hypertrophic cardiomyopathy (HCM). The key objectives are to: Define the contribution and phenotypic manifestations of established HCM disease genes in diverse, non-referral populations. Assess the pathogenicity of candidate HCM genes and establish a platform to evaluate variants of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on leveraging deep learning to link normal variation in aortic valve hemodynamics to the pathogenesis of aortic stenosis. The $722,299 award to The Regents of the University of California, San Francisco (UCSF), with a period of performance from August 1, 2025 to July 31, 2030, will enable UCSF to measure aortic valve...